Synonym
Pelrinone Free Base; Pelrinona; Pelrinonum
IUPAC/Chemical Name
5-Pyrimidinecarbonitrile, 1,4-dihydro-2-methyl-4-oxo-6-((3-pyridinylmethyl)amino)-
InChi Key
NZXHFDXOCVIYLO-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H11N5O/c1-8-16-11(10(5-13)12(18)17-8)15-7-9-3-2-4-14-6-9/h2-4,6H,7H2,1H3,(H2,15,16,17,18)
SMILES Code
N#CC1=C(NCC2=CC=CN=C2)NC(C)=NC1=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
241.25
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Scatina JA, Hicks DR, Kraml M, Cayen MN. Metabolic disposition and pharmacokinetics of pelrinone, a new cardiotonic drug, in laboratory animals and man. Eur J Drug Metab Pharmacokinet. 1990 Jan-Mar;15(1):37-48. doi: 10.1007/BF03190126. PMID: 2384116.
2: Hajdu J, Adams G, Lee HK. Preformulation study of pelrinone hydrochloride. J Pharm Sci. 1988 Nov;77(11):921-5. doi: 10.1002/jps.2600771104. PMID: 3225750.
3: Patelunas DM, Carmint WJ, Willis JZ, Colatsky TJ, Fenichel RL. Comparative antithrombotic activities of the phosphodiesterase inhibitors pelrinone (AY-26,768), AY-31,390 and milrinone. Thromb Res. 1991 Jun 1;62(5):389-400. doi: 10.1016/0049-3848(91)90012-l. PMID: 1896959.
4: Kitzen JM, McCallum JD, Harvey C, Morin ME. Antithrombotic activity of the phosphodiesterase III inhibitor pelrinone in a canine model of coronary artery thrombosis: enhancement of efficacy with concurrent alpha 2-adrenergic antagonism. J Cardiovasc Pharmacol. 1991 Dec;18(6):777-90. doi: 10.1097/00005344-199112000-00001. PMID: 1725888.
5: Bagli J, Bogri T, Palameta B, Rakhit S, Peseckis S, McQuillan J, Lee DK. Chemistry and positive inotropic effect of pelrinone and related derivatives. A novel class of 2-methylpyrimidones as inotropic agents. J Med Chem. 1988 Apr;31(4):814-23. doi: 10.1021/jm00399a023. PMID: 2832602.
6: Kitzen JM, McCallum JD, Pirozzi CT, Colatsky TJ. Potentiation of phosphodiesterase inhibitor antithrombotic activity with alpha-2 adrenergic blockade. Life Sci. 1991;48(7):PL31-5. doi: 10.1016/0024-3205(91)90548-p. PMID: 1671293.
7: Greenberg SS, Diecke FP, Cantor E, Peevy K, Tanaka TP. Inhibition of sympathetic neurotransmitter release by modulators of cyclic GMP in canine vascular smooth muscle. Eur J Pharmacol. 1990 Oct 23;187(3):409-23. doi: 10.1016/0014-2999(90)90368-g. PMID: 1981554.
